Specialty Cardiometabolic Sales Rep – Rare Disease Launch

TSP, a Syneos Health company; Fort Snelling Unorganized Territory (MN); On-site; USD 160,000 - 180,000; Full time

Benefits offered by this job

Competitive base salary

Incentive compensation

Equity (RSUs)

Car allowance program

Comprehensive benefits

Job summary

Arrowhead Pharmaceuticals seeks experienced Specialty Sales Representatives to launch and grow our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), for patients with rare cardiovascular conditions.

Role emphasizes prescriber activation, clinical depth, and cross-functional collaboration with IDNs, Market Access, and patient services to drive durable utilization, with ~30% travel and strong field execution.

Qualifications

• Bachelor's degree or equivalent; minimum 5 years of pharmaceutical sales experience.
• Proven success launching or expanding complex therapies requiring access navigation and clinical depth.
• 3+ years in specialty, rare disease, or cardiovascular areas preferred.

Responsibilities

• Develop and execute data-driven territory business plans aligned to brand strategy and launch objectives.
• Deliver compliant, clinically accurate product education within approved labeling to prescribers.
• Build and sustain relationships with healthcare professionals and institutional stakeholders.
• Navigate IDNs and coordinate with Market Access to support pull-through.
• Collaborate with Marketing, Medical Affairs, Market Access, Health IT, and Patient Services for territory execution.
• Travel ~30% to regional and national meetings; overnight travel may be needed.

Skills

Territory planning

Account management

Data-driven mindset

Clinical data interpretation

Communication skills

Presentation skills

Relationship-building

Business acumen

Organizational skills

Education

Bachelor's degree or equivalent

Tools

CRM software

Job description

Arrowhead Pharmaceuticals seeks experienced Specialty Sales Representatives to launch and grow our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), for patients with rare cardiovascular conditions.

Role emphasizes prescriber activation, clinical depth, and cross-functional collaboration with IDNs, Market Access, and patient services to drive durable utilization, with ~30% travel and strong field execution.